复方苦参注射液联合新辅助化疗对宫颈癌临床效果及生存期的影响  

Effect of Compound Kushen Injection and Neoadjuvant Chemotherapy on Cervical Cancer and Survival

作　　者：杨雪艳[1] 胡宝玉[1] 姜亚涛[2] YANG Xueyan;HU Baoyu;JIANG Yatao(Shangqiu Medical College,Shangqiu 476000,Henan,China;Ultrasonography Department,Shangqiu First People＇ s Hospital,Shangqiu 476000,Henan,China)

机构地区：[1]商丘医学高等专科学校,河南商丘476000 [2]商丘市第一人民医院超声科,河南商丘476000

出　　处：《中华中医药学刊》2018年第10期2520-2524,共5页Chinese Archives of Traditional Chinese Medicine

基　　金：河南省教育厅科学技术研究重点项目(14B320011);商丘市科技发展计划项目(131146)

摘　　要：目的：探讨复方苦参注射液联合新辅助化疗对宫颈癌的临床效果与生存期的影响。方法：宫颈癌患者152例,按照随机数字的方法分为对照组和观察组,每组76例,对照组患者采取新辅助化疗方案,观察组患者在新辅助化疗方案的基础上使用复方苦参注射液,对治疗的效果进行对比。结果：观察组患者的治疗效果优于对照组,数据差异具有统计学意义（z=6. 103,P 〈0. 05）,在两组患者的各项不良反应情况中,只有白细胞下降的数据差异具有统计学意义（P 〈0. 05）,观察组低于对照组,其余项目数据差异均不具有统计学意义（P〉 0. 05）,对照组患者的生存时间中位数为13. 325个月,观察组患者的生存时间中位数为16. 816个月,数据差异具有统计学意义（χ^2=4. 424,P 〈0. 05）,对照组和观察组治疗前的CD3^＋,CD4^＋,CD8^＋,CD4^＋/CD8^＋,CD＋16＋56数据比较差异无统计学意义（t=0. 028,0. 496,0. 226,0. 000,0. 255,P〉 0. 05）。治疗后,对照组的CD3^＋,CD4^＋,CD4^＋/CD8^＋,CD＋16＋56数据低于治疗前,数据差异具有统计学意义（t=2. 099,2. 221,45. 940,2. 083,P 〈0. 05）,CD8^＋数据高于治疗前,数据差异具有统计学意义（t=3. 379,P 〈0. 05）,观察组的CD3^＋,CD4^＋,CD4^＋/CD8^＋,CD＋16＋56数据高于治疗前,数据差异具有统计学意义（t=12. 095,6. 429,21. 761,6. 895,P 〈0. 05）,CD8^＋数据低于治疗前,数据差异具有统计学意义（t=3. 053,P 〈0. 05）。结论：利用复方苦参注射液联合新辅助化疗对宫颈癌患者进行治疗,可以改善患者的治疗效果和免疫功能,稳定治疗过程中不良反应的发生,提高患者的生存质量和生存率,值得在临床工作中应用。Objective：To investigate the clinical effect and survival time of Compound Kushen Injection and Neoadjuvant Chemotherapy in the treatment of cervical cancer. Methods： 152 patients with cervical cancer according to the random number method were divided into the control group and the observation group,76 cases in each group. The control group＇s patients were treated with neoadjuvant chemotherapy and the observation group＇s patients on the basis of neoadjuvant chemotherapy used Compound Kushen Injection. We compared the effect of treatment. Result： The treatment effect of the observation group was better than that of the control group,and the difference was statistically significant（ z =6. 103,P〈0. 05）. Among the two groups＇ adverse reactions,only the white blood cell decline data difference was statistically significant（ P〈0. 05）. The observation group＇s was lower than that of the control group and the remaining item data differences were not statistically significant（ P〉0. 05）. The median survival time of the control group was 13. 325 months,and the median survival time of the observation group was 16. 816 months,and the difference was statistically significant（ χ^2= 4. 424,P〈0. 05）. There was no significant difference in CD3^＋,CD4^＋,CD8^＋,CD4^＋/CD8^＋ and CD＋16＋56 before and after treatment in the control group and the observation group（ t = 0. 028,0. 496,0. 226,0. 000,0. 255,P〉0. 05）. After treatment,the control group＇s CD3^＋,CD4^＋,CD4^＋/CD8^＋ and CD＋16＋56 were lower than those before treat-ment,and the difference was statistically significant data（ t = 2. 099,2. 221,45. 940,2. 083,P〈0. 05）. CD8^＋ was higher than that before treatment,and the data had statistically significant difference（ t = 3. 379,P〈0. 05）. CD3^＋,CD4^＋,CD4^＋/CD8^＋ and CD＋16＋56 of the observation group were higher than those before treatment,and the difference was statistically significant（ t = 12. 095,6. 429,21. 761,6. 895,P〈0. 05）,and CD8^�

关 键 词：复方苦参注射液 化疗 宫颈癌 

分 类 号：R737.33[医药卫生—肿瘤]